Ideaya Biosciences Stock Today
| IDYA Stock | USD 26.79 0.19 0.71% |
Performance0 of 100
| Odds Of DistressLess than 43
|
Ideaya Biosciences is trading at 26.79 as of the 25th of November 2024, a 0.71 percent increase since the beginning of the trading day. The stock's open price was 26.6. Ideaya Biosciences has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Ideaya Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of February 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of May 2019 | Category Healthcare | Classification Health Care |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. The company has 86.43 M outstanding shares of which 9.31 M shares are currently shorted by private and institutional investors with about 12.62 trading days to cover. More on Ideaya Biosciences
Moving together with Ideaya Stock
| 0.65 | ME | 23Andme Holding | PairCorr |
| 0.89 | VALN | Valneva SE ADR | PairCorr |
| 0.68 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Ideaya Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ideaya Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President, CoFounder | Yujiro Hata | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIdeaya Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ideaya Biosciences' financial leverage. It provides some insight into what part of Ideaya Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ideaya Biosciences (IDYA) is traded on NASDAQ Exchange in USA. It is located in 7000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 124 people. Ideaya Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.32 B. Ideaya Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 86.43 M outstanding shares of which 9.31 M shares are currently shorted by private and institutional investors with about 12.62 trading days to cover.
Ideaya Biosciences currently holds about 268.62 M in cash with (115.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.83.
Check Ideaya Biosciences Probability Of Bankruptcy
Ownership AllocationThe majority of Ideaya Biosciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ideaya Biosciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ideaya Biosciences. Please pay attention to any change in the institutional holdings of Ideaya Biosciences as this could imply that something significant has changed or is about to change at the company.
Check Ideaya Ownership Details
Ideaya Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Adage Capital Partners Gp Llc | 2024-06-30 | 2.1 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.9 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 1.6 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | |
| Bvf Inc | 2024-09-30 | 1.4 M | |
| Avidity Partners Management Lp | 2024-09-30 | 1.4 M | |
| Ra Capital Management, Llc | 2024-09-30 | 1.3 M | |
| Fiera Capital Corporation | 2024-06-30 | 1.3 M | |
| Sofinnova Ventures | 2024-06-30 | 1.2 M | |
| Fmr Inc | 2024-09-30 | 12.6 M | |
| Blackrock Inc | 2024-06-30 | 6.8 M |
Ideaya Biosciences Historical Income Statement
Ideaya Stock Against Markets
Ideaya Biosciences Corporate Management
| Mick OQuigley | Chief Development | Profile | |
| Stu Dorman | Chief Officer | Profile | |
| Paul Stone | CFO VP | Profile | |
| JD Esq | Chief Secretary | Profile | |
| Matthew MD | VP Oncology | Profile | |
| Esq JD | Gen VP | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ideaya Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Ideaya Stock refer to our How to Trade Ideaya Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ideaya Biosciences. If investors know Ideaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ideaya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.33) | Revenue Per Share 0.051 | Quarterly Revenue Growth (0.03) | Return On Assets (0.16) | Return On Equity (0.21) |
The market value of Ideaya Biosciences is measured differently than its book value, which is the value of Ideaya that is recorded on the company's balance sheet. Investors also form their own opinion of Ideaya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ideaya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ideaya Biosciences' market value can be influenced by many factors that don't directly affect Ideaya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ideaya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ideaya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ideaya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.